News

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...
A new study found weight loss injections may help reduce the risk of dementia and stroke in people who are obese and have ...
Biocon plans to introduce generic versions of the weight-loss drug Wegovy in India and Canada by 2027, according to CEO Siddharth Mittal.
Research from ENDO 2025 reveals that GLP-1 anti-obesity medications not only aid in weight loss but also improve testosterone ...
In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide ...
Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...
Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...
GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...
Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...
Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027.